Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

Huber, Veronica; Vallacchi, Viviana; Fleming, Viktor; Hu, Xiaoying; Cova, Agata; Dugo, Matteo; Shahaj, Eriomina; Sulsenti, Roberta; Vergani, Elisabetta; Filipazzi, Paola; Laurentiis, Angela De; Lalli, Luca; Guardo, Lorenza Di; Patuzzo, Roberto; Vergani, Barbara; Casiraghi, Elena; Cossa, Mara; Gualeni, Ambra Vittoria; Bollati, Valentina; Arienti, Flavio; Braud, Filippo de; Mariani, Luigi; Villa, Antonello; Altevogt, Peter; Umansky, Viktor; Rodolfo, Monica; Rivoltini, Licia

doi:10.1172/jci98060

Cited by 206 publications

(217 citation statements)

References 75 publications

Supporting

Mentioning

197

Contrasting

Order By: Relevance

“…A few years ago, significant differences had already been reported between the EVs released by tumour cells, which induce immunoregulation, compared to the EVs from immune cells, which induce immunomodulation [65]. A few examples have already been reported in this review [48,50,62]. Improvements developed recently are focused on the treatment of single or various cancers.…”

Section: Diagnosis and Therapymentioning

confidence: 81%

“…A final possibility is another manipulation, making it possible for the EVs to remove molecules from their target cells [6,62,63]. Various approaches have already been developed.…”

Section: Diagnosis and Therapymentioning

confidence: 99%

“…This combination, however, is not always successful. Therapy in this case consists of the prevention or elimination of the EV mechanisms of action [62,74]. These effects are at least potentially critical because, together with the cross-talk of cancer cells with stromal cells, they play substantial roles in the establishment of cancer.…”

Section: Diagnosis and Therapymentioning

confidence: 99%

See 2 more Smart Citations

Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases

Meldolesi

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Two types of extracellular vesicles (EVs), exosomes and ectosomes, are generated and released by all cells, including immune cells. The two EVs appear different in many properties: size, mechanism and site of assembly, composition of their membranes and luminal cargoes, sites and processes of release. In functional terms, however, these differences are minor. Moreover, their binding to and effects on target cells appear similar, thus the two types are considered distinct only in a few cases, otherwise they are presented together as EVs. The EV physiology of the various immune cells differs as expected from their differential properties. Some properties, however, are common: EV release, taking place already at rest, is greatly increased upon cell stimulation; extracellular navigation occurs adjacent and at distance from the releasing cells; binding to and uptake by target cells are specific. EVs received from other immune or distinct cells govern many functions in target cells. Immune diseases in which EVs play multiple, often opposite (aggression and protection) effects, are numerous; inflammatory diseases; pathologies of various tissues; and brain diseases, such as multiple sclerosis. EVs also have effects on interactive immune and cancer cells. These effects are often distinct, promoting cytotoxicity or proliferation, the latter together with metastasis and angiogenesis. Diagnoses depend on the identification of EV biomarkers; therapies on various mechanisms such as (1) removal of aggression-inducing EVs; (2) EV manipulations specific for single targets, with insertion of surface peptides or luminal miRNAs; and (3) removal or re-expression of molecules from target cells.

show abstract

Section: Diagnosis and Therapymentioning

confidence: 81%

“…A final possibility is another manipulation, making it possible for the EVs to remove molecules from their target cells [6,62,63]. Various approaches have already been developed.…”

Section: Diagnosis and Therapymentioning

confidence: 99%

Section: Diagnosis and Therapymentioning

confidence: 99%

See 1 more Smart Citation

Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases

Meldolesi

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Secondly, because of the complexity and diversity of miRNA‐mRNA interaction, the impact of MV‐delivered miRNAs on the target cells may be quite extensive, potentially avoiding the undesired effects caused by switching a single target gene on or off . Many studies have shown that MVs delivering miRNAs are involved in the occurrence and development of many diseases . As a strategy to alter the type and quantity of extracellular miRNAs to gain therapeutic advantage, specific miRNAs or their inhibitors can be added to specific MVs .…”

Section: Existing Problems Of Mvs and The Clinical Prospectsmentioning

confidence: 99%

“…137 Many studies have shown that MVs delivering miRNAs are involved in the occurrence and development of many diseases. 131,138,139 As a strategy to alter the type and quantity of extracellular miRNAs to gain therapeutic advantage, specific miRNAs or their inhibitors can be added to specific MVs. 140 Future studies may focus on tailored recombinant MVs with unique cassettes of miRNAs for therapeutic benefits.…”

Section: The Clinical Prospect Of Mvsmentioning

confidence: 99%

The role of microvesicles containing microRNAs in vascular endothelial dysfunction

Shu

Tan

Miao

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Many studies have shown that endothelial dysfunction is associated with a variety of cardiovascular diseases. The endothelium is one of the primary targets of circulating microvesicles. Besides, microRNAs emerge as important regulators of endothelial cell function. As a delivery system of microRNAs, microvesicles play an active and important role in regulating vascular endothelial function. In recent years, some studies have shown that microvesicles containing microRNAs regulate the pathophysiological changes in vascular endothelium, such as cell apoptosis, proliferation, migration and inflammation. These studies have provided some clues for the possible roles of microvesicles and microRNAs in vascular endothelial dysfunction‐associated diseases, and opened the door towards discovering potential novel therapeutic targets. In this review, we provide an overview of the main characteristics of microvesicles and microRNAs, summarizing their potential role and mechanism in endothelial dysfunction, and discussing the clinical application and existing problems of microvesicles for better translational applications.

show abstract

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Xiong

Wang

2021

Advanced Biology

View full text Add to dashboard Cite

Cancer is the outcome of the conflict between the host immune system and cancer cells. The crosstalk between immune cells and tumor cells within the tumor microenvironment (TME) influences tumor progression and metastasis. Many studies have clarified the cellular and molecular events that can induce cancer cells to escape immune surveillance, including those involving tumor‐induced myeloid cell‐mediated immunosuppression. Emerging evidence indicates that tumor‐infiltrating myeloid cells (TIMs) accelerate tumor growth and induce angiogenesis, metastasis, and therapy resistance once converted into potent immunosuppressive cells. Here, how tumor infiltrating myeloid cells participate in tumor immune evasion and the prospects of these cells in cancer immunotherapy are discussed.

show abstract

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

Cited by 206 publications

References 75 publications

Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases

Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases

The role of microvesicles containing microRNAs in vascular endothelial dysfunction

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Contact Info

Product

Resources

About